Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

physicians prescribing VELCADE," said Christophe Bianchi, M.D., Executive Vice President, Commercial, Millennium. "The future of VELCADE is even more exciting as we look to expand into front-line multiple myeloma with several combinations that have the potential to deliver the strongest long- term survival for patients."

-- Phase III VISTA Trial in Front-Line Multiple Myeloma (MM) -- The

Company announced that the results of the large, randomized, Phase III

VISTA trial in patients with newly diagnosed MM showed that the therapy

of VELCADE, melphalan and prednisone demonstrated a highly

statistically significant improvement, compared with melphalan and

prednisone alone, across all efficacy endpoints, including time to

progression, complete remission rate, progression free survival and

overall survival. Side effects were manageable and included those seen

in previous VELCADE trials. Based on these positive data, the control

arm of the trial was stopped early to allow patients still being

treated with melphalan and prednisone to have VELCADE added to their

therapy. The Company now expects to file a supplementary new drug

application (sNDA) for use of VELCADE in patients with newly diagnosed

MM in December 2007.

-- Compendia Listing in Front-Line MM -- In October 2007, the national

compendia organization DrugPoints Systems included VELCADE as a

recommended therapy for use in newly diagnosed multiple myeloma

patients.

-- Label Expansion in MM -- In October 2007, the U.S. Food and Drug

Administration (FDA) granted approval for VELCADE use, without dose

adjustments, in patients with impaired kidney function, including those

requiring dialysis. Impaired kidney function is a common complication

related to MM, affecting approximately 30 percent of patients at

diagnos
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 18 Opsona Therapeutics, a,biotechnology company focused on ... diseases, today announced the,completion of an EUR18M ($23M) ... expand both at an operational and clinical level. ... and Seroba Kernel,Life Sciences all participated in the ...
... Forschungsgemeinschaft (DFG, German Research Foundation) has announced that ... high-risk research projects. The Joint Committee of Germany,s ... approved funding for two new Reinhart Koselleck Projects. ... Professor Reinhard Drner, an atomic physicist from Frankfurt, ...
... found that tiny nanoparticles could be twice as likely ... liquids than previously believed. This opens up a ... in living cells, polymer composites, and high-tech foams, ... ways of further artificially enhancing this new found sticking ...
Cached Biology Technology:Opsona Therapeutics Closes EUR18M Funding 2Opsona Therapeutics Closes EUR18M Funding 3Opsona Therapeutics Closes EUR18M Funding 4Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects 2Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects 3Nanoparticles double their chances of getting into sticky situations 2
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
(Date:4/17/2014)... researchers have detected new early-warning signs of the potential ... have far-reaching implications for the diagnosis and treatment of ... million Americans. , "We had not expected to see ... stages," said Ann Elsner, professor and associate dean in ... the study. "We set out to study the early ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... international consortium of 15 institutions from 12 European ... Norway, Romania, Sweden, The Netherlands, UK) has started ... The name stands for ,Biodiversity and Ecosystem Services: ... the effectiveness of arguments used for biodiversity protection ...
... the Arctic Ocean, the frozen soils within this region keep ... the Earth,s atmosphere. This sequestered carbon is more than 250 ... United States in the year 2009. As global temperatures slowly ... upon the carbon cycle when the permafrost thaws and releases ...
... metal-organic frameworks, with their nanoscopic pores and incredibly ... gas storage. But with millions of different structures ... University research team has developed a computational method ... in the discovery process. The new algorithm automatically ...
Cached Biology News:Preparing for a thaw: How Arctic microbes respond to a warming world 2Preparing for a thaw: How Arctic microbes respond to a warming world 3More promising natural gas storage? 2